A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 08 Jan 2018 Results (n=2536) of pooled analysis of NCT01106625, NCT01106677, NCT01137812 and NCT02025907 trials assessing effect of Canagliflozin on health related quality of life and patients' satisfaction published in The Patient - Patient-Centered Outcomes Research
- 11 Jun 2016 Results of a post-hoc analysis published in a Janssen media release.
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.